FINWIRES · TerminalLIVE
FINWIRES

Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month

By

Revolution Medicines' (RVMD) once-daily oral Rasonque tablets for the treatment of metastatic pancreatic cancer are available in the US at a price of $39,800 for a 30-day supply, the company said Wednesday in a regulatory filing.

The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

Price: $215.95, Change: $+4.57, Percent Change: +2.16%

Related Articles

Wire

Update: Worley Fiscal 2026 Underlying EPS, Aggregated Revenue Down; Shares Hit Six-Year Low

(Updates to add stock movement in the headline and the last paragraph.)Worley (ASX:WOR) logged AU$0.782 in underlying earnings per basic share for fiscal 2026, compared with AU$0.902 a year ago, a Wednesday filing showed.Analysts polled by FactSet expected AU$0.77.For the 12 months ended June 30, aggregated revenue was AU$12.02 billion versus AU$12.05 billion previously, the Australia-listed provider of engineering and project delivery services added. Analysts surveyed by FactSet projected AU$11.73 billion.The board proposed a final dividend of AU$0.25 per share, unchanged from a year earlier, payable Sept. 30 to shareholders of record as of Sept. 2.The company guided for fiscal 2027 underlying earnings before interest, taxes, and amortization growth, and for aggregated revenue growth, in the mid-to-high single-digit range.Its shares fell nearly 11% in recent trading on Wednesday and earlier hit their lowest since August 2020.

ASX:WOR
Wire

Update: HEICO Fiscal Q3 Earnings, Revenue Rise

(Updates to add share movement in the fifth paragraph.)HEICO (HEI) reported late Tuesday a fiscal Q3 earnings of $1.67 per diluted share, up from $1.26 a year earlier.Analysts polled by FactSet expected $1.51.Revenue for the quarter ended July 31 was $1.41 billion, up from $1.15 billion a year ago.Analysts expected $1.35 billion.Shares of the company rose 2.5% in after-hours trading.

$HEI
Wire

Spyre Halts Stand-Alone Rheumatoid Arthritis Drug Development; Shares Fall After Hours

Spyre Therapeutics (SYRE) said its experimental rheumatoid arthritis drug SPY072 failed to meet the company's internal performance threshold needed to justify further stand-alone development, prompting the halt of its monotherapy RA program.The drug delivered statistically significant improvements over placebo on several efficacy measures and showed a tolerable safety profile with no drug-related serious adverse events, the company said Tuesday in a statement.Spyre said it will now evaluate SPY072 in combination regimens and in other autoimmune indications, with additional clinical readouts expected in Q4.Spyre shares fell 12% in after-hours trading.

$SYRE